InsidersTradesSigma
Follow the NURIX THERAPEUTICS INC share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.6bn. The latest transaction was disclosed on 4 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: CHRISTINE RING. Every trade is accessible without an account.
Analysts rate NURIX THERAPEUTICS INC Strong Buy (bullish), based on 16 analysts. Average price target: US$33.13.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
NURIX THERAPEUTICS INC is a biopharmaceutical company focused on developing innovative therapies based on protein degradation. It is listed on NASDAQ under the symbol NRIX.